TITLE

Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma

AUTHOR(S)
Evans, D. J.; Barnes, P. J.; Spaethe, S. M.; van Alstyne, E. L.; Mitchell, M. I.; O'Connor, B. J.
PUB. DATE
December 1996
SOURCE
Thorax;Dec1996, Vol. 51 Issue 12, p1178
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66084902

 

Related Articles

  • Literature Reviews: Allergy and Immunology. Lampe, John B.; Melton, Jr, A. L. // Clinical Pediatrics;Nov1998, Vol. 37 Issue 11, p704 

    Discusses the abstract of a report on the antiinflammatory effects of leukotriene receptor antagonists. Utilization of an in vivo model of allergen exposure known as segmental allergen challenge; Advantages of the technique.

  • leukotriene receptor antagonists. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p466 

    An encyclopedia entry for "leukotriene receptor antagonists" is presented. It refers to a group of antiallergy drugs administered to prevent the symptoms of mild to moderate asthma. Leukotriene receptor antagonists work by blocking the effects of leukotrienes. Adverse events associated with...

  • A risk-benefit assessment of antileukotrienes in asthma. Smith, L.J. // Drug Safety;Sep1998, Vol. 19 Issue 3, p205 

    The antileukotriene drugs are the first new therapeutic agents approved for the treatment of asthma in more than 20 years. The currently available compounds are orally active and either prevent the cysteinyl leukotrienes from binding to and activating the cysLT-1 receptor in the lung...

  • Platelet-Activating Factor Antagonists: Current Status in Asthma. Gomez, F.P.; Rodriguez-Roisin, R. // BioDrugs;2000, Vol. 14 Issue 1, p21 

    Platelet-activating factor (PAF) is a potent lipid-derived mediator of inflammation that is considered to have a potential role in the pathogenesis of asthma. PAF is produced by many cells associated with asthmatic inflammation and has the ability to evoke some of the clinical hallmarks of...

  • Antileukotriene Drugs in Childhood Asthma: What is Their Place in Therapy? Selvadurai, H.; Mellis, C. // Pediatric Drugs;Sep/Oct2000, Vol. 2 Issue 5, p367 

    Leukotriene antagonists are a new class of anti-inflammatory drugs which have shown clinical efficacy in the management of asthma. However, their role in paediatric asthma is still unclear. In essence, while there are theoretical reasons as to why leukotriene antagonists would be of use in the...

  • SKUTECZNOŚĆ LEKÓW ANTYLEUKOTRIENOWYCH U PACJENTÓW Z WSPÓŁISTNIENIEM ASTMY I ALERGICZNEGO NIEÅ»YTU NOSA. RUBINSZTAJN, RENATA; CHAZAN, RYSZARDA // Problemy Terapii Monitorowanej;sep2009, Vol. 20 Issue 3, p193 

    Leukotriens are very important mediators of the allergic diseases. Montelucast derived by lipoxygenation of arachidonic acid with 5-lipoxygenaze activaiting protein. Leukotrienes act by leukotriene receptors one for LTB4 and second for cys-LTs (LTC4 i LTD4). Montelukast and zafirlucast belongs...

  • Montelukast. Markham, A.; Faulds, D. // Drugs;Aug1998, Vol. 56 Issue 2, p251 

    â–´ Montelukast is a selective antagonist of the leukotriene D (LTD) receptor. In patients with asthma, montelukast 5 to 250 mg/day attenuated LTD-induced bronchoconstriction and, at a dosage of 10mg, significantly reduced early and late airway response to allergen (dust mite extract)...

  • Leukotriene Antagonists Offer a New Mechanism for Asthma Control. Capriotti, Teri // MEDSURG Nursing;Oct99, Vol. 8 Issue 5, p318 

    Examines the effectiveness of leukotriene antagonists as an anti-inflammatory medication for asthma. Description of leukotrienes; Forms of corticosteroid control of inflammation; Indications for leukotriene antagonists; Implications of leukotriene antagonists.

  • Enhanced Cysteinyl-Leukotriene Type 1 Receptor Expression in T Cells from House Dust Mite-Allergic Individuals following Stimulation with Der p. Thivierge, Maryse; Turcotte, Sylvie; Rola-Pleszczynski, Marek; Stankova, Jana // Journal of Immunology Research;3/31/2015, Vol. 2015, p1 

    In order to determine the potential for allergen to modulate T cell expression of the CysLT1 receptor and responsiveness to leukotrienes, peripheral blood mononuclear cells from house dust mite-allergic or nonallergic individuals were incubated with D. pteronyssinus allergen (Der p). Baseline...

  • Involvement of Leukotriene B4 in Substance P-Induced Itch-Associated Response in Mice. Andoh, Tsugunobu; Katsube, Nobuo; Maruyama, Masayuki; Kuraishi, Yasushi // Journal of Investigative Dermatology;Dec2001, Vol. 117 Issue 6, p1621 

    Intradermal injection of substance P elicits an itch sensation in human subjects and an itch-associated response in mice. The substance P-induced itch-associated response in mice is not inhibited by antihistamine. Therefore, the mechanisms of substance P-induced itch-associated response are...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics